D. E. Shaw & Co., Inc. Pacira Bio Sciences, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 240,439 shares of PCRX stock, worth $5.06 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
240,439
Previous 206,016
16.71%
Holding current value
$5.06 Million
Previous $6.95 Million
1.08%
% of portfolio
0.01%
Previous 0.01%
Shares
25 transactions
Others Institutions Holding PCRX
# of Institutions
287Shares Held
48.7MCall Options Held
156KPut Options Held
623K-
Black Rock Inc. New York, NY7.91MShares$166 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$108 Million0.0% of portfolio
-
Frontier Capital Management CO LLC1.91MShares$40.3 Million0.55% of portfolio
-
State Street Corp Boston, MA1.9MShares$40.1 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.88MShares$39.6 Million0.09% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $965M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...